What is William Blair's Estimate for Genmab A/S Q3 Earnings?

Key Points

• William Blair has raised its Q3 2025 earnings estimates for Genmab A/S to $0.46 per share, up from the previous estimate of $0.44, with a full-year earnings estimate of $1.45 per share.
• Genmab A/S's stock has experienced a 5.6% decline recently, with a current market price of $21.43 and a consensus price target of $37.80.
• Institutional investors have significantly increased their stakes in Genmab A/S, demonstrating confidence in the company's potential, particularly as the stock has a consensus rating of "Moderate Buy."

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - William Blair upped their Q3 2025 earnings estimates for Genmab A/S in a note issued to investors on Thursday, August 7th. William Blair analyst M. Phipps now forecasts that the company will earn $0.46 per share for the quarter, up from their prior estimate of $0.44. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S's FY2025 earnings at $1.72 EPS, FY2026 earnings at $1.79 EPS, FY2027 earnings at $2.43 EPS and FY2028 earnings at $3.25 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion.

Several other brokerages have also commented on GMAB. Truist Financial increased their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $37.80.

Genmab A/S Stock Performance

Genmab A/S stock traded up $0.24 during midday trading on Monday, hitting $22.91. 353,366 shares of the company's stock were exchanged, compared to its average volume of 1,441,581. The company has a market cap of $14.70 billion, a PE ratio of 11.51, a P/E/G ratio of 6.42 and a beta of 0.95. The firm has a 50-day moving average of $21.75 and a two-hundred day moving average of $20.88. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $27.94.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd raised its holdings in shares of Genmab A/S by 102.8% during the 1st quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company's stock worth $111,816,000 after acquiring an additional 2,895,179 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Genmab A/S by 152.3% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company's stock valued at $71,367,000 after buying an additional 2,084,966 shares during the period. Deep Track Capital LP purchased a new stake in Genmab A/S in the 4th quarter valued at about $41,740,000. First Trust Advisors LP raised its holdings in Genmab A/S by 3.5% in the 2nd quarter. First Trust Advisors LP now owns 1,770,310 shares of the company's stock valued at $36,575,000 after buying an additional 60,504 shares during the period. Finally, Brandywine Global Investment Management LLC raised its holdings in Genmab A/S by 1.6% in the 2nd quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company's stock valued at $36,047,000 after buying an additional 27,372 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.